Telomerase as a cancer vaccine

Pancreatic cancer vaccine to be tested on thousands of BritonsCopper news
Clinical trials of a pancreatic cancer vaccine have begun in the UK.

According to the BBC (TeloVac pancreatic cancer vaccine trial launched in UK), studies of the drug TeloVac, developed by the South Korean company KAEL-GemVax, are conducted with the support of the British cancer research charity Cancer Research.

The TeloVac vaccine contains the enzyme telomerase, which is synthesized in excess by malignant cells and provides uncontrolled growth of tumor tissue. The purpose of vaccination is to stimulate the immune response and the production of cells capable of recognizing cancerous tumors by the presence of telomerase and attacking them.

Clinical trials of the vaccine will be held in 53 British hospitals. More than a thousand patients who have pancreatic cancers at a late stage of development were selected to participate in the trials. Along with the introduction of the vaccine, British cancer patients will receive chemotherapy. Members of the control group of study participants will receive only chemotherapeutic treatment.

The organizers intend to obtain reliable results on the effectiveness of vaccination within a year after the start of the trials. Later in 2011, KAEL-GemVax plans to conduct research on a lung cancer vaccine created using a similar technology.

Malignant neoplasms of the pancreas are one of the most dangerous types of cancer. According to the World Health Organization, more than 95 percent of pancreatic cancer patients die within five years after the tumor is detected. On average, such patients live from three to six months from the moment of diagnosis.

Portal "Eternal youth" http://vechnayamolodost.ru18.04.2011